Cath Trigwell - Concepedia

Author

Cath Trigwell

AstraZeneca (United Kingdom)

Also Known As

C. Trigwell, Cath B. Trigwell, Cath Trigwell, Cath B. Trigwell

Publications

587

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (France)

About

Cath Trigwell is an author at AstraZeneca (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	325
2	Natural Sciences	2	2	28
3	Biochemistry	2	2	28
4	Cell Biology	2	2	297
5	Molecular Biology	1	1	36

Cath Trigwell

Publications

584

Citations

H-Index

Page 1

	Year	Citations
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ Sarit Schwartz, John Wongvipat, Cath Trigwell, Cancer Cell Signal TransductionSignaling PathwayCell RegulationPten-mutated TumorsFeedback Suppression	2014	261
AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer D. Mark Hickinson, Teresa Klinowska, Georgina Speake, Clinical Cancer Research	2010	118
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson, Molecular Cancer Therapeutics	2014	99
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers Kevin Hudson, Urs J. Hancox, Cath Trigwell, Molecular Cancer Therapeutics	2016	42
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors Bernard Barlaam, Judith Anderton, Peter Ballard, ACS Medicinal Chemistry Letters Her3 ReceptorsMolecular BiologyTumor BiologyHer2 Kinase DomainSignaling Pathway	2013	36
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bernard Barlaam, Peter Ballard, Robert H. Bradbury, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryNeutral 5-Substituted 4-AnilinoquinazolinesBiochemistryMedicineActive Inhibitors	2007	18
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bernard Barlaam, David Acton, Peter Ballard, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryFunctional SelectivityMedicineActive Inhibitors	2008	10

Page 1